

Dear Editors:

Thank you for these helpful comments concerning our manuscript entitled “Tislelizumab Combination with Chemotherapy Successfully Converted Unresectable Advanced Penile cancer into Complete Surgical Excision: A Case Report and Literature Review”(Manuscript ID: 78285). We have carefully checked and made corrections throughout our manuscript. The point-to-point responses to the reviewers’ comment are as follows:

Reviewer #1:

Scientific Quality: Grade D (Fair)

Language Quality: Grade B (Minor language polishing)

Conclusion: Major revision

Specific Comments to Authors: The case report entitled “Tislelizumab Combination with Chemotherapy Successfully Converted Unresectable Advanced Penile cancer into Complete Surgical Excision: A Case Report and Literature Review” by Dr. Long and colleagues, reports on a case of a 58-year-old male with locally advanced Penile squamous cell carcinoma (PSCC), with bulky, fixed inguinal lymph node metastasis complicated within genital skin ulcers, who completed inguinal lymph node dissection and achieved pathologically complete response via conversion therapy by immunotherapy plus chemotherapy. The text is in general interesting, clear and easy to follow. However, more introductory notions should be included. Moreover, more supporting references and notions in the field should be included. I have several observations, and I am therefore recommending a major revision(please see below for additional comments for improving the ms).

Comments

1. More information on Penile cancer etiopathogenesis, mutational burden, therapy and prognosis should be included. For instance, a fraction of cases are HPV-driven.

Answer: Thanks for careful reading and helpful comments. We have added information about the pathogenesis, mutation load, treatment and prognosis of penile cancer.

2.More supporting references should be included, for instance here “but multiple small size cohort studies have demonstrated that nearly half of patients do not benefit from neoadjuvant chemotherapy alone, which made it urgent to find new and effective treatments.” However, additional sentences spread throughout the text are lacking in supporting references

Answer: We carefully examined the full text and added relevant supporting references in the manuscript for checking.

3.immune checkpoint inhibitors (ICIs) represent a promising therapeutic approach as stated (DOI: 10.3389/fonc.2022.832047). For completeness of information, this notion and supporting reference should eb included

Answer: We have carefully read the article you mentioned, and it is indeed very meaningful, and was quoted.

4.Introduction the correct name is Programmed cell death protein 1 (PD-1)

Answer: Revised, thanks!

5.Sections should be separated with a space

Answer: Revised, thanks!

6.CASE PRESENTATION section, “21 days after surgery” I discourage starting a sentence with a number

Answer: Revised, thanks!

7.Figure 1 is not mentioned in the text, while it should be mentioned and described

Answer: We have added a description of Figure 1 to the article. Thanks!

8.Several sentence are in gray instead of black. Please fix this problem

Answer: Fixed, thanks!

Reviewer #2:

Scientific Quality: Grade D (Fair)

Language Quality: Grade C (A great deal of language polishing)

Conclusion: Major revision

Specific Comments to Authors: A good use of combination therapy with immunotherapy and chemotherapy, but the case report is let down by the large number of grammatical errors Was a ethical committee clearance obtained ? as this is not the standard of care and is an experimental therapy

Answer: We thank you for careful reading and helpful comments. 1.We have checked and corrected grammatical errors throughout our manuscript. In addition, we have also enlisted a colleague with excellent proficiency in English to proofread our manuscript. 2. This study was approved by the Institutional Review Board and Human Ethics Committee of Guang'an People's Hospital, and written informed consent was obtained from the patient.

Reviewer #3:

Scientific Quality: Grade B (Very good)

Language Quality: Grade B (Minor language polishing)

Conclusion: Accept (General priority)

Specific Comments to Authors: The authors may add the pharmacological name of the EGFR inhibitors used in this case.

Answer: We thank you for helpful comments and have added the pharmacological name of the EGFR inhibitors used in this case.

4 LANGUAGE POLISHING REQUIREMENTS FOR REVISED MANUSCRIPTS SUBMITTED BY AUTHORS WHO ARE NON-NATIVE SPEAKERS OF ENGLISH

Authors are requested to send their revised manuscript to a professional English language editing company or a native English-speaking expert to polish the manuscript further. When the authors submit the subsequent polished manuscript to us, they must provide a new language certificate along with the manuscript.

Answer: We thank you for the editor's suggestion. A professional English language editing have been done before and after submission.



Editing Certificate

This document certifies that the manuscript
Tislelizumab Combination with Chemotherapy Successfully Converted Unresectable Advanced Penile cancer into Complete Surgical Excision: A Case Report

prepared by the authors
Xiang-Yu Long, Shuang Zhang, Lian-sha Tang, Xiang Li, Ji-Yan Liu

was edited for proper English language, grammar, punctuation, spelling, and overall style by one or more of the highly qualified native English speaking editors at AJE.

This certificate was issued on **March 23, 2022** and may be verified on the [AJE website](#) using the verification code **8C56-6F8A-C3D4-4F43-8BCP**.

Neither the research content nor the authors' intentions were altered in any way during the editing process. Documents receiving this certification should be English-ready for publication; however, the author has the ability to accept or reject our suggestions and changes. To verify the final AJE edited version, please visit our verification page at [aje.com/certificate](#). If you have any questions or concerns about this edited document, please contact AJE at support@aje.com.

AJE provides a range of editing, translation, and manuscript services for researchers and publishers around the world. For more information about our company, services, and partner discounts, please visit [aje.com](#).

This document certifies that the manuscript

Conversion Therapy for Advanced Penile Cancer with Tislelizumab Combined with
Chemotherapy: A Case Report and Literature Review

prepared by the authors

Xiang-Yu Long, Shuang Zhang, Lian-sha Tang, Xiang Li, Ji-Yan Liu

was edited for proper English language, grammar, punctuation, spelling, and overall style
by one or more of the highly qualified native English speaking editors at SNAS.

This certificate was issued on **September 12, 2022** and may be verified
on the [SNAS website](#) using the verification code **A991-5C47-6C7C-7607-BFAD**.

Neither the research content nor the authors' intentions were altered in any way during the editing process. Documents receiving this certification
should be English-ready for publication; however, the author has the ability to accept or reject our suggestions and changes. To verify the final
SNAS edited version, please visit our verification page at [secure.authorservices.springernature.com/certificate/verify](#).
If you have any questions or concerns about this edited document, please contact SNAS at [support@as.springernature.com](#).

SNAS provides a range of editing, translation, and manuscript services for researchers and publishers around the world.
For more information about our company, services, and partner discounts, please visit [authorservices.springernature.com](#).

We appreciate for editors' warm work earnestly, and tried our best to improve the
manuscript and hope that the correction will meet with approval. We look forward
hearing from you regarding our submission. We would be glad to respond to any
further questions and comments that you may have.

Once again, thank you for your suggestions and wish you a happy day.

Best wishes,

The first author:

XiangYu Long, Ph.D., Prof.

Department of Oncology, Guang'an People's Hospital

No. 1, Section 4, Binhe Road, Guang'an District, Guang'an City

SiChuan 638550 CHINA

Tel: 86-23-2600315

Email: 371256871@qq.com